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Abstract
Herpes simplex virus type-1 (HSV-1) establishes latency in peripheral neurons, creating a permanent source of recurrent
infections. The latent genome is assembled into chromatin and lytic cycle genes are silenced. Processes that orchestrate
reentry into productive replication (reactivation) remain poorly understood. We have used latently infected cultures of
primary superior cervical ganglion (SCG) sympathetic neurons to profile viral gene expression following a defined
reactivation stimulus. Lytic genes are transcribed in two distinct phases, differing in their reliance on protein synthesis, viral
DNA replication and the essential initiator protein VP16. The first phase does not require viral proteins and has the
appearance of a transient, widespread de-repression of the previously silent lytic genes. This allows synthesis of viral
regulatory proteins including VP16, which accumulate in the cytoplasm of the host neuron. During the second phase, VP16
and its cellular cofactor HCF-1, which is also predominantly cytoplasmic, concentrate in the nucleus where they assemble an
activator complex on viral promoters. The transactivation function supplied by VP16 promotes increased viral lytic gene
transcription leading to the onset of genome amplification and the production of infectious viral particles. Thus regulated
localization of de novo synthesized VP16 is likely to be a critical determinant of HSV-1 reactivation in sympathetic neurons.
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Introduction
The remarkable success of the herpesviruses as infectious agents
stems from their ability to alternate between productive (acute)
replication and latency; distinct genetic programs that achieve very
different outcomes for both the virus and the host cell. Acute
replication results in release of infectious particles by cell lysis and
produces a strong immunological stimulus, whereas in latency the
lifespan of the host cell is often extended and the viruses use
various strategies to minimize antigen presentation. By alternating
between these two programs, herpesviruses can often remain in
their host indefinitely but at the same time retain the ability to
spread through reactivation, a process whereby latent virus
reenters the productive replication cycle and infectious particle
are shed at the surface.
The prototype example for this successful strategy is herpes
simplex virus type-1 (HSV-1), a widespread human pathogen that
infects epithelial cells in the oral cavity, eyes and other regions of
mucosa. Latency is established in the ganglia of peripheral nerves
that innervate these sites, creating a lifelong reservoir that is
shielded from immune clearance (reviewed in [1,2]). Intermittent
reactivation events give rise to infectious particles that travel to the
periphery by anterograde axonal transport. Continuous reemer-
gence of virus from the permanent neuronal reservoir ensures
lifelong transmission and is often associated with clinical disease.
How the HSV-1 regulates the transition from one program to
the other is not well understood. Latent genomes reside in the
nucleus of the host neuron as extra-chromosomal circles that are
assembled into chromatin resembling that of the host [3,4].
Transcription is limited to the latency-associated transcripts
(LATs) that are spliced into a stable 1.5 to 2.0-kb intron and
processed into several microRNAs [5,6,7]. The rest of the viral
transcriptome corresponding to 80 or so genes is effectively
silenced. Although the details are incomplete, it appears that lytic
gene transcription is blocked by a combination of mechanisms
involving histone modifications that create a repressive chromatin
structure, recruitment of factors that prevent the assembly of pre-
initiation complexes and the absence of activators need to
stimulate RNA polymerase II recruitment and elongation [3,4].
Chromatin immunoprecipitation (ChIP) studies have shown that
the histones associated with the promoter regions of the key
regulatory genes carry modifications such as trimethylated histone
H3 lysine-9 (H3K9me3) and lysine-27 (H3K27me3) that are
typical of facultative heterochromatin [8,9]. Also present are
polycomb (PcG) repressor subunits that may promote chromatin
compaction and limit RNA polymerase elongation. Additional
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silencing complex that recruits the histone deacetylases HDAC1 or
2 and the demethylase LSD1 [10,11,12]. When latent episomes
undergo reactivation, this heterochromatic signature is replaced
with chromatin that is permissive for transcription, enabling the
expression of the full repertoire of lytic genes needed to build new
infectious virus and neutralize host defenses [13].
Despite intense study by many laboratories there is still much to
be learned about the molecular processes that maintain the latent
program and orchestrate the transition back into productive
replication. Studies have been hampered by the very small
numbers of infected neurons in ganglia obtained from human
cadavers or animal models, our limited understanding of the
signaling pathways that connect natural reactivation stimuli to the
latent episome and difficulties in manipulating HSV-infected
ganglia in order to test the roles of cellular factors implicated in the
process. To circumvent these issues we have taken advantage of a
robust cell culture model of HSV-1 latency that uses primary
sympathetic neurons isolated from the superior cervical ganglia
(SCG) of unborn rats [14]. Homogenous neuron cultures are
maintained in the presence of nerve growth factor (NGF) and
HSV-1 latency can be established with wild type virus by infection
in the presence of acyclovir (ACV). Lytic gene products and
infectious virus disappear within a few days but the viral genomic
DNA (average of c.25 copies/neuron) remains and LAT RNA can
be readily detected in the nuclei of .20% of the neurons by
fluorescent in situ hybridization, signifying the presence of latent
virus. At this stage, ACV can be removed and cultures maintained
for up to five weeks without reactivation [15]. Latency is
dependent on continuous NGF signaling and interruption of the
TrkA/PI3-kinase/Akt branch of the pathway leads to reactivation
[14].
This study focuses on the program of viral lytic gene
transcription that initiates after NGF signaling is interrupted.
Classic studies in non-neuronal cell types have shown that acute
(lytic) HSV-1 replication follows an ordered gene expression
cascade that can be divided into three temporal phases:
immediate-early (IE, a), early (E, b) and late (L, c) [16,17].
During low multiplicity infections, the IE phase is initiated by the
tegument protein VP16 (also termed a-TIF, UL48, vmw65), which
collaborates with cellular factors to drive IE gene transcription
[18,19,20]. The IE proteins then act as positive regulators of the E
genes, leading to amplification of the HSV-1 DNA genome and
transcription of the L genes, which encode structural components
of the viral particle, including the tegument protein VP16.
Whether reactivation follows the same transcription program is
uncertain, not least because the context of the viral genome is
radically different in the two situations. At the onset of
reactivation, the viral DNA is incorporated into ordered
chromatin consisting of regularly spaced nucleosomes, whereas
at the beginning of acute infection cycle the DNA is essentially
nucleosome-free. Additionally, regulatory proteins such as VP16
that incorporated into the virion tegument are almost certainly
absent at the beginning of reactivation.
Using pharmacological inhibition of PI3-kinase to achieve
synchronous reactivation, we find that viral lytic mRNAs
accumulate in two discrete waves (dubbed Phase I and II) that
differ in the need for viral protein synthesis, DNA replication and
the initiator factor VP16. In Phase I, lytic transcripts of all three
kinetic classes accumulate simultaneously. New viral protein
synthesis is not required, consistent with a short-term reversal of
episome silencing. Genome amplification begins in Phase II and is
followed by infectious virus production. VP16 accumulates in the
cytoplasm during Phase I but most interestingly, does not
contribute to viral transcription until Phase II, when nuclear
VP16 is first detected. During acute infections, VP16 assembles an
activator complex on viral promoters in the nucleus through
interactions with host factors Oct-1 and HCF-1 [21,22,23], and
providing human Oct-1, which has a higher affinity for VP16 than
its rodent counterparts, to the neurons increases viral transcript
levels during Phase II, arguing for the assembly of an equivalent
VP16-induced complex. We conclude that reactivation follows a
unique program of gene expression initiated by a transient reversal
of host-mediated gene silencing and suggest that regulated entry of
VP16 into the neuronal nucleus represents a host-imposed barrier
that must be overcome for successful viral reactivation to occur.
Results
Sequential cascade of viral mRNA accumulation during
acute replication in sympathetic neurons
As a prelude to our analysis of reactivation in sympathetic
neurons, we profiled viral mRNA accumulation during acute
replication (Figure 1). Week-old neuron cultures were infected
with recombinant HSV-1 GFP-Us11 at a multiplicity of infection
of 3 PFU/neuron (MOI=3). Under these conditions, the virus
replicated productively and the majority of neurons expressed the
GFP-Us11 fusion protein within the first day. RNA was collected
at intervals between 0 and 12 h of infection and analyzed by
quantitative reverse transcription PCR (qRT-PCR) using primers
specific to lytic transcripts representing each kinetic class: IE
(ICP27/UL54), E (DNA polymerase/UL30), leaky-late/c1
(VP16/UL48) and true-late/c2 (tegument phosphoprotein ICP1-
2/UL36). The first transcripts were detected within 3 h and
became increasingly abundant at later time points. Importantly,
we found that the accumulation of these mRNAs followed the
classic IE-E-L profile (Figure 1A).
To pinpoint the onset of viral genome amplification, total DNA
was also collected at each time point and assayed by qPCR using
primers complimentary to a region in the UL30 gene (Figure 1B).
Aside from a small increase in DNA content between 0 and 3 h
that likely reflects the binding and uptake of viral particles into the
neurons, robust amplification of the viral genome began between 6
Author Summary
Herpes simplex virus is a widespread human pathogen
that establishes permanent infections in nerves innervat-
ing the lips, eyes and other surfaces. The viral DNA
genome is transported to the neuronal nucleus located in
the nerve ganglia, where it establishes a semi-dormant
state known as latency. Periodically, latent viruses undergo
reactivation, a process that leads to the production of
infectious particles, allowing for person-to-person trans-
mission and acting as the major source for painful lesions
(cold sores) and other more severe pathological outcomes.
How latency and reactivation are controlled is not well
understood. Using cultured nerve cells, we show that
reactivation involves a unique, two stage program of viral
gene expression. We find that the essential control protein
VP16 is synthesized during the first stage but accumulates
in the cytoplasm rather than the nucleus where it
functions. Nuclear entry is determined by host signaling
and marks the onset of the second reactivation stage. This
work provides important new insights into the virus-host
interaction and reveals a natural control point that could
be used in innovative therapies that for the first time
target the latent virus.
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transcripts from UL36 (Figure 1A and 1D), which is defined as a
replication-dependent (true-late or c2) gene [24]. To confirm that
the increase in genome content reflected virus-directed replication,
the time course was repeated in the presence of phosphonoacetic
acid (PAA), an inhibitor of the virus-encoded DNA polymerase
(Figure 1B). As expected, there was no increase in DNA content in
the presence of the inhibitor, even at 12 h. By definition, leaky-late
(c1) and true-late (c2) genes are distinguished by the degree of
sensitivity to PAA and other inhibitors of viral DNA synthesis.
Accordingly, VP16 mRNA (c1) showed only a limited decrease in
the presence of PAA (Figure 1C), whereas the levels of UL36
mRNA (c2) were significantly decreased (Figure 1D). Expression of
GFP-Us11 also conforms to true-late kinetics and was sensitive to
PAA (data not shown). Thus, productive HSV-1 infection in SCG-
derived neurons follows a sequential program of gene expression
Figure 1. Acute replication of HSV-1 in SCG neurons follows the canonical ordered cascade of mRNA accumulation. (A) Primary
neurons were isolated from superior cervical ganglia (SCG) of E21 rats, cultured for 7 days in the presence of 5 mM aphidicolin and 20 mM5 -
fluorouracil to eliminate proliferating cells, and then infected with HSV-1 GFP-Us11 at a multiplicity of 3 plaque forming units per neuron (MOI=3).
RNA was collected at 0, 3, 6, 9, and 12 h post-infection (p.i.) and analyzed by quantitative reverse transcription PCR (qRT-PCR) to determine the
relative levels of viral immediate-early (ICP27), early (UL30), c1 leaky-late (VP16) and c2 true-late (UL36) transcripts. Values represent the average and
standard error from the mean from three independent infection experiments. (B) Neuron cultures were treated with the viral DNA polymerase
inhibitor phosphonoacetic acid (PAA, 300 mg/ml) for 1 h (hatched bars) or mock treated (filled bars) and then infected with HSV-1 GFP-Us11. Total
DNA was prepared at the indicated times and the relative levels of viral genomic DNA determined by quantitative (qPCR) using primers
complementary to the HSV-1 UL30 gene. Input DNA was normalized by qPCR detection of the rat RPL19 gene. (C, D) Analysis of c1 leaky-late (VP16)
and c2 true-late (UL36) transcript levels in the presence or absence of PAA.
doi:10.1371/journal.ppat.1002540.g001
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In agreement with an earlier study using SCG neurons [25], we
find that the duration of the lytic program is 2 to 3 times longer in
primary neurons than in non-neuronal cells such as rat embryo
fibroblasts (Figure S1).
Viral mRNAs accumulate in two discrete phases during
reactivation
Ex vivo studies of reactivation have relied on the analysis of
latently infected ganglia that are surgically axotomized from the
animal and then explanted into culture. Under these circumstanc-
es the neurons are severely stressed and it is likely that multiple
reactivation triggers occur. Alternatively, reactivation can be
induced by physiological stress prior to analysis (discussed in [26]).
After explant, viral lytic mRNAs are synthesized very rapidly,
making it difficult to establish the order of events and limiting the
opportunities for manipulating the neuronal environment by non-
pharmacological means. Mindful of these issues, we turned to the
SCG neuron culture model as a tractable experimental system to
study the first stages of reactivation. Treatment of latently-infected
SCG cultures with the phosphatidyl inositol-3 kinase (PI3-K)
inhibitor LY294002, is sufficient to activate latent HSV-1
episomes, resulting in the expression of a lytic reporter (GFP-
Us11) in 15–20% of the neurons within 48 h [14]. This provides a
single, defined reactivation stimulus that simplifies subsequent
analyses.
Latently infected cultures were established over a one-week
period in the presence of 100 mM acyclovir (ACV) to suppress lytic
replication and then reactivated following the scheme outlined in
Figure 2A. Once latency was established, fresh media containing
LY294002 and lacking ACV was added to induce reactivation.
After inducing reactivation, total RNA was collected at successive
time points over a four-day period and analyzed by qRT-PCR
using viral primer sets normalized to 18S rRNA (Figure 2B). A
baseline for each lytic mRNA was established from samples
collected when the inducer was first applied (abundance ranges
from 94 copies/sample for UL30 to 347 copies/sample for VP16)
and all other values are expressed relative to these low but
measurable levels. The analysis revealed a protracted time course
of lytic mRNA accumulation compared to the acute infection
studies (see Figure 1A), with a strong but transient accumulation of
IE, E and L viral mRNAs at 20 h, followed by a decline between
20 and 25 h and then a gradual accumulation from 48 to 96 h, the
last time point. The analysis shown summarizes the data from
three independent experiments prepared from separate neuron
preparations made on different dates. Mock treatment with
DMSO resulted in no reproducible change in baseline levels over
a 72 h period (data not shown). In all of these experiments, and in
others not shown here, we observed a similar protracted profile
corresponding to a discernable spike in lytic mRNA accumulation
at 15 to 20 h post-induction, a striking decrease at around 25 h
and then a second, more gradual, rise at later times. This profile is
clearly very different from the rapid and sequential accumulation
of lytic mRNAs observed during acute infection of similar cultures.
We will refer to these two discrete periods or waves of lytic mRNA
accumulation as Phase I and Phase II.
A simple explanation for the biphasic profile is that a limited
number of (primary) reactivation events produce infectious virus
that subsequently spreads to neighboring cells and replicate further
as (secondary) acute infections. We ruled out this out by including
WAY-150138, a stable compound that prevents encapsidation of
the DNA genome and blocks spread of infectious virus [27,28].
Repeating the reactivation time course in presence of WAY-
150138 produced a very similar, biphasic profile (Figure 2C),
indicating that secondary infection was not responsible for the
second peak of lytic mRNA accumulation.
It is known that brief exposure to the protein synthesis inhibitor
cycloheximide (CHX) is sufficient to induce HSV-1 reactivation in
both SCG and dorsal root ganglion neuron cultures [29]. To ask
whether the synthesis of viral proteins is required for Phase I, we
induced reactivation with LY249002 first and then maintained the
cultures for 10 h to allow the earliest reactivation steps to proceed
before CHX (10 mg/ml) was added. At this time, viral lytic
transcripts remained at base line levels making it highly unlikely
that any viral proteins had been synthesized. RNA was collected
after a further 10 h in the presence of CHX (i.e. at 20 h post-
induction with LY249002) and analyzed by qRT-PCR (Figure 2D).
When compared to mock treated cultures, no significant changes
were observed in the levels of lytic mRNAs, indicating that Phase I
initiates normally in the absence of viral protein synthesis.
Next we sought to determine when viral genome amplification
begins. DNA was collected at successive intervals and analyzed by
qPCR (Figure 3A). Under these assay conditions we can reliably
detect an increase in viral DNA content of 15% or greater (data
not shown). No increase in viral DNA content was observed until
the 48-h time point, which corresponds to Phase II and was not
seen when the experiment was repeated in the presence of the
PAA. The lack of demonstrable amplification during Phase I (15
and 20 h post induction) at least within the limits of the assay, was
especially interesting given that we could readily detect represen-
tative late gene transcripts at 20 h. To examine this more closely,
we compared the expression of UL36 mRNAs in the presence or
absence of PAA at 20 h (Figure 3B). No significant difference was
observed, showing that accumulation of UL36 mRNA in Phase I
was replication-independent. By contrast, inclusion of PAA
decreased the accumulation of UL36 mRNA during Phase II in
a reproducible and significant manner (P-value,0.045).
We also performed plaque assays to detect infectious virus
particles (Figure 3C). Acknowledging the sensitivity issues
associated with this biological assay [27], we were unable to
detect plaques until 48 h post LY294002 treatment, with a
significant increase in plaque number from 72 h onwards. This
suggests that infectious virus is not assembled until well into Phase
II, concomitant with viral genome amplification and reinforces the
notion that the transition from Phase I to Phase II does not reflect
secondary infection.
Reactivation requires the transactivation function of
VP16
VP16 is essential for HSV-1 replication, functioning in the
assembly of the tegument layer and as a potent transactivator of
the IE genes, which in turn drive the expression of the E genes
[30,31]. Recombinant viruses have been characterized that carry
mutations in VP16 that preserve the essential tegument forming
function but selectively impair the transactivation function, either
by preventing the formation of the VP16-induced complex on
DNA response elements found in each IE promoter [32] or by
removing the C-terminal transactivation domain [33,34]. Previous
work has shown these mutants can still establish latency in animal
models, and depending on the reactivation assay used, can display
severe defects in reactivation [35,36]. To examine the contribution
of VP16 to LY294002-induced reactivation in the SCG system, we
performed infection studies using in1814, a derivative of strain
17syn
+ that contains a 12-bp insertion at codon 397 (Figure 4A)
[32]. Neuron cultures were infected in the presence of ACV with
equal titers (MOI=1) of in1814 or a repaired version (in1814R)
that behaves similar to wild type strain 17syn
+ and allowed to
establish latency. To obtain equivalent titers each virus stock was
Neuronal Reactivation Program of Latent HSV-1
PLoS Pathogens | www.plospathogens.org 4 February 2012 | Volume 8 | Issue 2 | e1002540Figure 2. During reactivation, HSV-1 exhibits a biphasic profile of viral transcripts in SCG neurons. (A) Scheme showing a typical
reactivation experiment. Neuron cultures were established and then infected with HSV-1 GFP-Us11 (MOI=1) in the presence of 100 mM acyclovir
(ACV). Latency was established over a 7-day period before re-feeding with fresh media lacking ACV. The next day, reactivation was induced with
20 mM LY294002. (B) Profile of viral mRNA accumulation in response to LY294002. RNA was collected at the indicated times and analyzed by qRT-PCR.
Values are normalized against the 0 h sample [ICP27, 171 copies/sample; UL5, 135 copies/sample; UL30, 94 copies/sample; VP16, 347 copies/sample
and UL36 130 copies/sample]. Data is derived from three or more independent cultures and reactivation experiments. (C) Reactivation profiling in the
presence of the viral DNA encapsidation inhibitor WAY150138 (20 mg/ml). (D) Transcript levels at 20 h post induction in the absence (2) or presence
(+) of protein synthesis inhibitor cyclohexamide (CHX, 10 mg/ml). To ensure cell viability, CHX was added 10 h after LY294002, prior to the appearance
of new viral transcripts.
doi:10.1371/journal.ppat.1002540.g002
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assayed on rat embryo fibroblasts in the presence of 5 mM
hexamethylene bisacetamide (HMBA), a differentiation agent that
overcomes the requirement for transactivation by VP16 during
productive replication at low multiplicity [37]. The in1814 and
in1814R viruses established latency at a similar frequency as
judged by quantitation of viral genomic DNA after six days in the
presence of ACV (Figure 4B). Slightly more genomes were
detected with in1814, however, this difference was not statistically
significant (P.0.29). The ability of in1814 to establish latency
mirrors its behavior in several latency models [33,35,36,38,39].
Next, latently infected cultures were induced with LY294002 and
the yield of infectious virus was determined by plaque assay on
Vero cells in the presence of HMBA (Figure 4C). In spite of the
similar numbers of genome at the time of induction, we observed a
profound difference in the yield of infectious virus. Indeed, over
multiple experiments we were unable to detect a single infectious
particle for in1814. This indicates that loss of the transactivation
function of VP16 has a highly deleterious effect on the ability of
HSV-1 to reactivate successfully in cultured neurons following a
specific stimulus. This agrees with previous studies using the
murine hyperthermal stress model for reactivation [36].
VP16 contributes to reactivation Phase II but not Phase I
To better understand the nature of the in1814 reactivation
defect, we measured the relative levels of viral mRNAs produced
by the mutant and rescued viruses in each reactivation phase
(Figure 4D). For ease of comparison, values for in1814 are shown
relative to the corresponding in1814R samples and the entire
profile for mRNA accumulation from in1814 is shown in Figure
S2A. When the two viruses are compared at 15 or 20 h post-
induction (Phase I), no significant differences were observed,
however at 72 h (Phase II) all five representative lytic mRNAs
were expressed at approximately 5-fold lower levels by in1814
compared to in1814R (Figure 4D). Likewise, no amplification of
the in1814 genome was detected (Figure S2B), consistent with the
inability of the mutant virus to produce infectious progeny. Thus
we conclude that the transactivation function of VP16 contributes
to lytic gene transcription during the Phase II only, and that
reduced expression of viral proteins results in a failure to replicate
the genome. This would account for the absence of infectious
progeny following reactivation.
Reduction of Phase II transcript levels using VP16 shRNA
An important caveat in using mutant viruses to study
reactivation is the possibility that the mutations alter some aspect
of the establishment of latency that subsequently impacts
reactivation. To circumvent this concern and independently
validate the striking phenotype of the in1814 virus, we developed
a short-hairpin RNA (shRNA) capable of depleting newly
synthesized VP16 from wild type virus. We have previously shown
that latently infected SCG neurons can be successfully infected
with lentiviruses without inducing reactivation and that shRNAs
delivered in this manner are effective at depleting endogenous
proteins [14]. The ability to deplete viral products in this system
was previously untested. Neurons were latently infected with the
HSV-1 GFP-Us11, allowed to establish latency and then
secondarily infected with lentiviruses encoding either the VP16
shRNA or a non-silencing control. The vector includes a
constitutive mCherry marker and visual inspection confirmed that
the majority of neurons were infected (data not shown). After 5
days of dual infection, LY294002 was added to the media and
reactivation allowed to proceed. VP16 depletion was confirmed by
qRT-PCR to detect VP16 mRNA (Figure S2C) and by
immunoblot of lysates prepared at 5 days post-induction
(Figure 4E). VP16 is required for tegument assembly and
accordingly, infectious virus was not detected in cultures
expressing the VP16 shRNA, corroborating the knockdown
(Figure 4F). More importantly, we compared the levels of lytic
transcripts at 15 and 20 h (Phase I) and 48 h (Phase II). As before,
we observed no significant difference in Phase I, but saw a 4 to 5-
fold reduction in each of the lytic mRNAs in Phase II (Figure 4G).
This result confirms the phenotype of the in1814 virus and
underscores the importance of VP16-mediated transactivation
during Phase II.
Human Oct-1 increases levels of viral mRNA in Phase II
VP16 is recruited to the TAATGARAT sequences found in
each HSV-1 IE promoter through physical association with HCF-
1 and the POU domain transcription factor Oct-1 [30]. Selection
of Oct-1 (also called POU2F1) is highly specific and the presence
of other POU proteins may actually antagonize the VP16-induced
complex by competing for the TAATGARAT sites. The Oct-1
POU DNA-binding domain is sufficient for VP16-induced
complex formation, with VP16 recognizing a solvent exposed
surface on the POU-homeo (POUH) subdomain [40]. Although
the amino acid sequence of the POU domain has been conserved
through vertebrate evolution (Figure 5A), there are four differences
between the POUH sequences of human and either rat or mouse
Oct-1 [41]. As a consequence, VP16 has a significantly lower
affinity for rodent Oct-1 and reduced ability to drive transcription
from reiterated TAATGARAT elements in murine 3T3 cells [42].
Whether this difference between rat and human Oct-1 has an
equivalent effect on the activity of the IE promoters in the context
of the reactivating virus is unknown. To address this, we used a
lentiviral expression vector to introduce human Oct-1 into rat
SCG neurons that were already latently infected with HSV-1
Us11-GFP. After the 5-day establishment period, separate cultures
were transduced with either a lentivirus expressing wild type
human Oct-1 or a control lentivirus expressing GFP. After a
further 5 days, reactivation was induced with LY294002 and RNA
samples prepared at regular intervals. Effective delivery of the Oct-
1 lentivirus was confirmed by qRT-PCR analysis using human
Oct-1 specific primers (Figure 5B). Amplification products were
readily detected in the samples containing the Oct-1 expression
lentivirus but not with the control virus and the levels remained
essentially unchanged through the time course of the experiment.
Analysis of viral lytic mRNAs performed in parallel revealed the
expected biphasic profile in both sets (data not shown). During
Phase I (15 to 20 h) no significant differences in transcript levels
were observed between neurons expressing human Oct-1 or GFP,
but in Phase II viral mRNA levels were increased of up to 5-fold in
the presence of human Oct-1 (Figure 5C).
To determine whether this increase was simply a consequence
of providing more Oct-1, we performed parallel infections with a
human Oct-1 derivative in which the two non-conserved residues
Figure 3. HSV-1 GFP-Us11 replication occurs in Phase II of reactivation. Latent cultures of SCG cells were induced with LY294002 as
described before. (A) Viral DNA Content was determined by qPCR at different times post-reactivation (p.r.) in the absence or presence of 300 mg/ml
PAA. (B) Quantitative RT-PCR analysis of VP16 and UL36 mRNA levels in the absence or presence of 300 mg/ml PAA during Phase I (15–20 h) and in
Phase II (48 h). (C) Number of infectious virus particles was determined by plaque assay.
doi:10.1371/journal.ppat.1002540.g003
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and methonine-33, highlighted in Figure 5A) were swapped to the
rodent equivalent (aspartic acid-30 and leucine-33). These two
residues are reported to have the greatest impact on VP16 binding
[42] and the deleterious effect of the combined mutation was
confirmed by gel-shift assay using in vitro translated Oct-1, VP16
and HCF-1 proteins (Figure 5D, E). Both wild type (lane 4) and
mutant human Oct-1 (lane 10) bind with similar efficiency to a
32P-labeled probe containing an (OCTA
+)TAATGARAT se-
quence from the HSV-1 ICP0 promoter [23]. As expected, wild
type Oct-1 supports VP16-induced complex (VIC) formation
(lanes 5–9) but this is reduced by 100-fold or greater with the
E30D/M33L mutation (lanes 11–15). Efficient lentiviral infection
for the mutant was evident by a strong qRT-PCR signal using
Figure 4. Transactivation function of VP16 is required during Phase II. (A) Structure of VP16 showing the 12-bp insertion (in1814) between
the structured N-terminal domain and the C-terminal activation domain (AD) that disrupts VP16-induced complex assembly [32]. (B) SCG neurons
were infected with mutant (in1814) or marker rescue (in1814R) viruses (MOI=1) in the presence of 100 mM acyclovir and maintained for 7 days before
measuring the relative amounts of viral genomic DNA by qPCR. (C) Reactivation was induced with 20 mM LY294002 in media lacking ACV and
maintained for 7 days before harvest and plaque assay to detect infectious virus. (D) Comparison of viral transcript levels during reactivation by
in1814 (‘M’) and in1814R (‘R’) at 15 and 20 h post-induction (Phase I) and at 72 h post-induction (Phase II). For each time point, transcript levels from
the in1814 (‘M’) sample were set to 1 and the value for the corresponding transcript from in1814R (‘R’) plotted as the fold difference. (E) Depletion of
VP16 using RNA interference. Latently infected neuron cultures were infected with a lentivirus expressing a VP16-specific short-hairpin RNA [shRNA]
(KD) or with a control lentivirus (Con). ShRNAs were allowed to accumulate for 5 days before reactivation was induced with LY294002 and allowed to
proceed for 5 days in media lacking ACV. Lysates were prepared and probed by immunoblotting to detect VP16 and the loading control, Rho-GDI. (F)
Quantitation of infectious virus by plaque assay. (G) Comparison of viral transcript levels in the absence of VP16. Values from the control culture are
plotted relative to the corresponding value from the VP16 shRNA (KD) culture.
doi:10.1371/journal.ppat.1002540.g004
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lower than with wild type. Importantly, we observed no significant
change in viral lytic mRNA levels in the Oct-1 E30D/M33L
transduced cultures, either in Phase I or in Phase II compared to
the control lentivirus expressing GFP (Figure 5C), indicating that
the stimulation observed by wild type human Oct-1 in Phase II is
most likely due to improved interactions with VP16. We conclude
from this experiment that the transactivation function provided by
VP16 in Phase II requires Oct-1, presumably through the
formation of a multi-protein complex on the TAATGARAT
elements found in each IE promoter.
VP16 is expressed in Phase I but remains in the
cytoplasm
Although the transactivation function of VP16 is dispensable for
Phase I, VP16 mRNA is readily detected (Figures 2–4). This
prompted us to ask when the VP16 protein is synthesized. To do
this we performed indirect immunofluorescence microscopy on
latently infected neurons undergoing reactivation (Figure 6). Using
a rabbit polyclonal antibody against VP16, we detected a strong
signal in approximately 5% of the neurons at the onset of
reactivation (0 h, see discussion), which rose to more than 20% of
the culture at 15 and 20 h, which corresponds to Phase I
(Figure 6A and 6B). The signal corresponds to VP16 because the
antibody recognizes a single species of the correct size on
immunoblots (Figure 4E), is absent from the remaining 80% or
more neurons in the cultures (Figure 6A) and can be suppressed or
eliminated by coinfection with the VP16 shRNA lentivirus (data
not shown).
Strikingly, at 0 h and later time points the VP16 signal was
preferentially localized to the soma (cell body) of the neurons
rather than the nucleus (indicated by arrow heads and counter-
stained with DAPI), an unexpected distribution for a transcription
factor. By contrast IE proteins ICP0 and ICP27 were detectable as
speckles in the nucleus during Phase I showing that multiple viral
antigens are expressed at this time and that nuclear uptake was not
inhibited (Figure S3). The cytoplasmic VP16 signal persisted
through the Phase I–II transition (25 h) and into Phase II (48 and
96 h), however most interestingly, a small but increasing number
of neurons showed a predominantly nuclear VP16 signal at 25 and
48 h (Figures 6A and 6C). The nuclear signal appeared diffuse
throughout the nucleoplasm and was excluded from the single
large nucleolus characteristic of neurons. This distribution is
consistent with a general association with chromatin, rather than
formation of discrete viral replication compartments within the
nucleus [43].
Localization of VP16 cofactor HCF-1 is regulated by
PI3-kinase inhibition
HCF-1 is nuclear in most cell types with the notable exception
of sensory neurons, where it accumulates in the cytoplasm [44].
Ganglia explant and other stresses, trigger relocalization of HCF-1
into the nucleus, where it can associate with HSV-1 IE gene
promoters [44,45]. In light of the dynamic localization of VP16 in
SCG neuron cultures, we also probed for HCF-1 using a
polyclonal antibody directed against the HCF-1C subunit
(Figure 7A). The immunofluorescence signal is widely dispersed
throughout the cytoplasm including the axons and dendrites
(upper panels). Nuclear sparing is clearly evident and the
cytoplasmic HCF-1 did not appear to co-localize with major
cytoplasmic organelles. When cultures are treated with LY294002
for 25 h, we saw significant accumulation of nuclear HCF-1 in
some but not all of the neurons (Figure 7A, lower panels).
Counting revealed a strong nuclear signal in more than 30% of the
LY294002-treated neurons (n=293) compared to less than 2% in
mock-treated cultures (n=1244) (Figure 7B). Control studies using
antibodies to the HCF-associated proteins Ash2L [46] and LSD-1
[11] revealed predominantly nucleoplasmic staining with obvious
nucleolar sparing, irrespective of treatment (Figure S4). Thus we
can reproduce the differential and dynamic localization of HCF-1
first described in murine trigeminal ganglia, and show for the first
time that HCF-1 localization can be manipulated by the inhibition
of a cellular signal transduction pathway critical for the
maintenance of HSV-1 latency.
Discussion
Latent infection of primary SCG neuron cultures provides a
powerful system to pick apart the mechanisms that control HSV-1
reactivation in response to defined physiological changes in the host
neuron. Viral and cellular regulatory factors can be more readily
manipulated in culture than in live-animal models and use of
relatively pure populations of neurons allows us to set aside
potentially confounding layers of control imposed by HSV-specific
CD8
+ T cells and other cell types resident in the ganglia. Thus
analyses can be focused on the intimate and fundamental
relationship between the latent virus and it’s host neuron. Using
this reductionist approach, we have profiled the transition from the
latent to lytic transcription programs after treating latently infected
cultures with a selective PI3-kinase inhibitor that interrupts NGF
signaling [14,29]. In contrast to acute infections, we find that lytic
mRNAs accumulate in two discrete waves - termed Phase I and
Phase II - that differ profoundly in their requirement for viral
Figure 5. Elevated Phase II viral transcript levels in neurons expressing human Oct-1. (A) Schematic of Oct-1 showing the location of the
POU DNA-binding domain near the middle of the protein and an alignment of the human, mouse and rat POU homeo (POUH) subdomain sequences.
The four variable positions are located in helix-1 and helix-2 and are numbered according to their position within the POUH sequence. A rodent-like
Oct-1 derivative (Oct-1E30D/M33L) was constructed by changing glutamic acid-30 and methionine-33 to the aspartic acid and leucine of the mouse/rat
sequence. (B) SCG neuron cultures were infected with HSV-1 GFP-Us11, maintained for 5 days in the presence of ACV and then infected with lentiviral
vectors encoding GFP or human Oct-1. After a further 5 days, ACV was removed and reactivation induced with 20 mM LY294002. RNA was collected at
intervals and analyzed by qRT-PCR using human Oct-1 specific primers. For each time point, values for each transcript were compared to those from
the GFP-expressing neurons (set to 1.0). (C) Relative levels of viral transcripts (ICP27, UL5, UL30, VP16 and UL36) after reactivation of HSV-1 GFP-Us11
in neurons expressing GFP, wild type human Oct-1 (WT) and human Oct-1E30D/M33L (MUT). (D) Wild type (WT) and E30D/M33L (MUT) versions of
human Oct-1, VP16 (residues 5–412, VP16DC) and the b-propeller domain of human HCF-1 (residues 1–380, HCF-1N380) were synthesized by in vitro
translation in the presence of
35S-methionine and visualized by 10% SDS-PAGE followed by autoradiography. (E) Assembly of the VP16-induced
complex (VIC) by rodent-like (E30D/M33L) Oct-1 is greatly reduced compared to wild type human Oct-1. Recombinant Oct-1, VP16 and HCF-1
proteins were assayed for VIC formation by gel shift assay using a
32P-labeled probe containing an (OCTA
+)TAATGARAT element from the HSV-1 ICP0
promoter [23]. The first three lanes are controls showing probe alone (lane 1), un-programmed rabbit reticulocyte lysate (lane 2), and a mix of lysates
containing recombinant VP16 and HCF-1 (lane 3). The shift formed by the rabbit Oct-1 present in the lysate is greatly enhanced by the presence of
either wild type or mutant human Oct-1 (lanes 4 and 10). A slower migrating complex (VIC) is formed by addition of VP16 and HCF-1 in the presence
of wild type Oct-1 (lane 5) and only weakly by the mutant (lane 11). Reducing the amount of wild type Oct-1 by 5, 10, 50 and 100-fold respectively
(lanes 6–9) reduces but does not eliminate this complex. No VIC is detected over a similar range of using mutant Oct-1.
doi:10.1371/journal.ppat.1002540.g005
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Accumulation of viral transcripts during Phase I was unaffected by
addition of the protein synthesis inhibitor CHX prior to the onset of
viral mRNA accumulation, indicating that changes in pre-existing
factors may be sufficient to bring about a generalized, but
apparently temporary, de-repression of the lytic transcriptome.
Studies published while this work was in revision also find that IE, E
and L transcripts accumulate concurrently in the presence of CHX
following explant-induced reactivation from the trigeminal ganglia
of mice infected by corneal inoculation [47]. Our data does not
provide evidence for the selective activation of key viral genes and
suggests instead that there is activation of a broad spectrum of lytic
genes. We acknowledge, however, that only a small fraction of the
lytictranscriptomehas beensurveyedand that exceptionsmayexist.
While Phase I appears to be unique to the reactivation program,
Phase II more closely resembles the ordered cascade seen during
acute infection of both neuronal and non-neuronal cells. Lytic
mRNA levels are enhanced by the transactivation function of the
Figure 6. VP16 is expressed during Phase I but is localized to the cytoplasm. (A) Detection of VP16 in latently infected neurons by indirect
immunofluorescence microscopy using an a-VP16 rabbit polyclonal antibody (red). Individual nuclei were visualized with DAPI (blue). Three
representative fields are shown from cover slips collected at 20 h post-induction (Phase I) and single fields from 48 and 96 h (Phase II). An arrowhead
is used to indicate the cell body of neurons with a predominantly cytoplasmic VP16 signal, whereas those displaying a strong nuclear VP16 signal are
indicated with an asterisk. Neurons that do not express VP16 are left unmarked but are evident from the DAPI stained nuclei. (B) Quantitation of the
immunofluorescence analysis. Numbers of VP16 positive neurons are expressed as a percentage of all neurons scored. Data is compiled from three
independent reactivation experiments. Between 500 and 3,000 neurons were scored per cover slip. (C) Percentage of VP16 positive neurons with a
predominantly nuclear rather than cytoplasmic a-VP16 signal.
doi:10.1371/journal.ppat.1002540.g006
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on viral DNA replication and this phase culminates in the
production of infectious virus. From the evidence obtained so far,
we favor the notion that Phase I might serve as a ‘priming’ stage
from which virus may or may not progress into a ‘production’ or
‘synthesis’ stage (Phase II). In this context, about a quarter of the
neurons engage in Phase I as judged by VP16 and ICP27
fluorescence, but it seems likely that a much smaller number
advance into Phase II as signified by either the presence of nuclear
VP16 (this study) or the accumulation of true-late protein Us11
(Us11-GFP) in the presence of a compound that prevents
secondary infection [14]. Further work is needed to establish the
exact relationship between entry of VP16 into the nucleus and
onset of Phase II-specific processes such as genome amplification
and virion assembly.
Initiator protein VP16 is synthesized in Phase I but evidently
does not contribute a necessary function until Phase II. Using two
strategies we show that in the absence of VP16-mediated
transactivation, the second phase of reactivation program proceeds
at a reduced level and ultimately does not yield infectious virus.
Thus we can conclude that VP16 is essential for reactivation in the
SCG model following interruption of NGF signaling. Whether this
is the result of insufficient transcription of the IE genes or loss of
some less well understood function of VP16 remains to be
addressed. A similar requirement for VP16 is observed in vivo
during reactivation from murine trigeminal ganglia in response to
thermal stress [36] but interestingly is not required for reactivation
from the same ganglia after axotomy/explant, which is generally
considered a more severe and multifaceted stimulus [35,48]. This
difference between assay approaches highlights the complex
nature of the reactivation literature in which a number of different
experimental systems have been used to explore the viral and
cellular requirements for reactivation [49]. Although different
conclusions have been drawn, the results are not necessarily
incompatible.
While speculative, the idea of two-stage process for synthesizing
and using VP16 (and possibly other viral regulatory factors) is
appealing because it mirrors the delivery of tegument proteins
including VP16 during acute infections [18,20]. This strategy
would perhaps allow HSV-1 to evaluate the capacity of the host
neuron to support virion production, which is both metabolically
demanding and involves extensive remodeling of the viral
chromatin, before proceeding to point that might threaten the
survival of the neuron or render the viral genome vulnerable to
innate defenses. Reactivation events that do not meet the
necessary criteria for completion of Phase II, for instance if there
was insufficient nuclear accumulation HCF-1 and/or VP16, may
even retain the option of re-establishing latency. This ability would
buffer the virus from wide scale reactivation under moderate stress
conditions and thereby help to maintain the latent reservoir.
Although the overall amounts of viral mRNA were similar in
samples collected during Phase I and Phase II this is unlikely to be
a true representation of the transcriptional activity at each stage.
Assuming that a smaller number of genomes progress into Phase
II, the actual rates of transcription for any given reactivating
episome will be much higher, consistent with the strong activator
functions associated with VP16 and HCF-mediated remodeling of
viral chromatin. In theory, this intriguing idea could be
substantiated or refuted by following the progression of individual
neurons through the reactivation program.
The transition from a repressed (silenced) chromatin state to one
that allows high levels of transcription requires the concerted
action of a variety of histone modifying enzymes and chromatin
remodeling factors. An active area of study, there is already
compelling evidence that HSV-1 uses a combination of viral and
cellular factors to overcome silencing imposed by polycomb (PcG)
repressor complexes [8], a REST/coREST/LSD1 repressor
complex [1,11] and possibly other mechanisms. ChIP studies of
chromatin isolated from infected ganglia have established that core
histones associated with the latent episome are enriched for
H3K27me3, a repressive mark that is the signature of control by
PcG proteins [8]. This and other repressive epigenetic marks are
lost during reactivation and replaced with di/trimethylated histone
H3 lysine-4 (H3K4me2/3), a mark of active transcription [50,51].
Future work will determine whether silencing marks are removed
at the onset of Phase I or are retained until Phase II, perhaps
providing an epigenetic imprint that facilitates re-establishment of
the latency program for genomes that do not progress into Phase
II.
Exhaustive studies in mammalian cell lines and more heterol-
ogous systems such as yeast have shown that the individual
components of the VP16-induced complex can recruit a variety of
factors that promote active transcription [46,50,51,52]. The well-
studied acidic activation domain of VP16 is capable of recruiting
or altering the activity of several general transcription factors, the
Mediator complex, histone acetyltransferases and ATP-dependent
chromatin remodeling factors as well as RNA polymerase II itself
(reviewed in [53]). Whether the same processes and interactions
apply during reactivation is not known. It is also worth noting that
HCF-1 can bind to a variety of cellular transcription factors either
directly or indirectly, and that some of these factors have binding
sites in the HSV-1 IE and E gene promoters [54]. Moreover,
HCF-1 is a component of several coactivators complexes,
including the Set1 histone H3K4 methyltransferase complexes
that is an active modifier of HSV-1 chromatin during acute
infections [52,55]. Thus it remains a possibility that under some
circumstances, the necessary chromatin-modifying activities are
recruited to viral chromatin through the association of HCF-1 and
cellular DNA binding proteins rather than VP16. This might
explain why the transactivation function of the VP16-induced
complex is not required under all reactivation circumstances
[35,48].
Figure 7. Relocalization of HCF-1 in response to PI3-kinase inhibition. (A) Confocal image showing a cluster of neuronal cell bodies probed
with a-HCF-1 rabbit polyclonal antibody (red) and a-neurofilament-200 (NF200) mouse monoclonal antibody (green) at 25 h post treatment with
LY294002 (lower panels) or vehicle (upper panels). Note HCF-1 signal throughout the cell body and axonal processes with sparing in the nucleus.
Nuclear accumulation is detected in one neuron (arrow) in the LY294002-treated sample. (B) Quantitation of neurons showing obvious nuclear HCF-1
at 25 h post treatment with LY294002 (+) or vehicle (2) (C) Model for the two-step reactivation program observed in sympathetic neurons induced
by inhibition of NGF signaling. The latent HSV-1 episome resides in the nucleus (‘N’) and is associated with histones carrying post-translational
modifications typical of repressed chromatin (red lollipops). HCF-1 is sequestered in the cytoplasm, whereas Oct-1 is presumed to be nuclear
throughout. Host-mediated alterations to episome chromatin during Phase I allows for generalized transcription of viral lytic genes. VP16 is
synthesized, but accumulates in the cytoplasm (‘C’), possibly through association with HCF-1. We speculate that a smaller number of animation
events advance to Phase II, coincident with the accumulation of VP16 and HCF-1 into the nucleus permitting the assembly of the VP16-induced
complex on viral IE promoters in association with Oct-1. This leads to the recruitment of additional chromatin modifiers that apply chromatin marks
associated with active transcription (green lollipops).
doi:10.1371/journal.ppat.1002540.g007
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draw a clear distinction between the overarching process of
reactivation that ends with the release of infectious progeny and a
more narrowly defined ability of the viral episome to transcribe
lytic genes. Feldman and colleagues used ‘spontaneous molecular
reactivation’ to describe events in which viral lytic genes are
abundantly expressed but no infectious virus is detected [56].
Whether reactivation is curtailed by the action of adjacent
immune cells within the ganglia or is intrinsic to the individual
neurons to remains to be established. More recently, Penkert and
Kalejta applied the succinct term ‘animation’ to describe the initial
departure from the latent program prior to the onset of virion
production [2]. This strikes us as a good descriptor for the Phase I
stage detailed for the first time in this study because it allows for a
flexible program in which the virus can either advance to full
reactivation or re-establish latency if certain thresholds are not
met.
Beyond the mechanistic details, partitioning of the reactivation
program into two discrete phases has important implications for
the control of HSV-1 latency by the host immune system. In the
absence of an applied reactivation stimulus, we found that up to
5% of the neurons in our cultures were VP16 positive by
immunofluorescence assay but otherwise the cultures lacked
obvious signs of reactivation such as strong GFP-Us11 expression
or detectable infectious particles. Although the levels of viral
antigen expression seem high compared to previous in vivo studies,
this is likely a reflection of the very high colonization rate (25–50%
of neurons) in this in vitro system ([14], unpublished studies). In
vivo, similar animation events will appear much less frequently
because far fewer neurons are colonized however these rare events
could still serve as the source of viral antigens detected by HSV-
specific CD8
+ T cells that infiltrate sensory ganglia in latently
infected animals [57]. By manipulating the Phase I–II transition, it
may be possible to propel a greater number of animation events
into active replication phase rendering the virus vulnerable to both
cell-mediated immunity and the action of current antiviral
compounds. This would offer a new and worthy strategy to target
the latent reservoir, a long-sought-after but elusive goal.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations laid out by the NIH Guide for the Care and Use
of Laboratory Animals. A detailed protocol for the isolation of rat
primary neurons was approved by the Institutional Animal Care
and Use Committee (IACUC # 101009) of the NYU Langone
Medical Center (PHS Assurance of Compliance Number: A3435-
01). Rats were euthanized by CO2 inhalation prior to ganglia
harvest.
Preparation of SCG neuron cultures
Primary neuron preparation, culture and infection was
performed using our established procedures [14]. Briefly, superior
cervical ganglia (SCG) were isolated from E21 Sprague DawleyH
rat pups, placed in Leibovitz’s L-15 medium supplemented with
2 mM L-glutamine, 0.4% D-glucose and incubated with 0.1%
trypsin at 37uC for 30 min. Next, ganglia were washed in C-
medium (minimum essential medium with Earle’s salts, 0.4% D-
glucose, 10% FBS, 2 mM L-glutamine) and dissociated by passing
through 21G and 23G needles and a 70 mm nylon cell strainer.
Dissociated cells were seeded in 24-well plates at a density of 4–
5610
4 cells per well with C-medium supplemented with NGF
(50 ng/ml, Harlan Bioproducts). To improve adherence, wells
were pre-coated with collagen (0.6 mg/ml, Millipore) and laminin
(2 mg/ml, Sigma). The following day, media was changed to NBM
(neural basal media, 0.4% D-glucose, 2 mM L-glutamine, 1x B-
27) supplemented with NGF and with aphidicolin (5 mM,
Calbiochem) and 5-fluorouracil (20 mM, Sigma) to remove
proliferating cells.
HSV-1 infection of SCG neuron cultures
For acute infections, cultures were maintained for 6 days as
described above and then incubated with HSV-1 (Patton) GFP-
Us11 (MOI=3) for 2 h at 37uC. Latent infections were established
by adding 100 mM acyclovir (ACV, Calbiochem) to the culture
media on day 6, infecting the following day with HSV-1
(MOI=1). After 2 h at 37uC, the media was replaced with
NBM with 50 ng/ml NGF and 100 mM ACV and maintained for
7 days to allow latency to establish. Cultures were induced to
reactivate with by replacing the media with fresh NBM containing
the PI3-kinase inhibitor LY294002 (Calbiochem, 20 mM) and
50 ng/ml NGF but omitting ACV. When using HSV-1 GFP-
Us11, individual wells were inspected prior to induction for GFP
fluorescence that might be indicative of low level spontaneous
reactivation, and discarded if positive. Typically no more than 10–
20% of cultures undergo spontaneous reactivation after mock
treatment, most likely due to the stress of handling.
Transcript analysis by quantitative reverse transcription
PCR (qRT-PCR)
Total RNA was prepared from neuron cultures using the
RNeasy Mini kit (QIAgen) with some minor modifications. After
washing with PBS, neurons were lysed in 350 ml RLT Buffer
(QRNeasy Mini Kit, QIAgen) and homogenized using QIAsh-
redder (QIAgen). The total volume was brought up to 900 ml with
water and treated with 90 mg/ml Protease K for 10 minutes at
55uC. RNA was precipitated with 450 ml of 100% ethanol and
applied to columns provided by the kit. Columns were washed as
recommended and eluted with RNase-free water. To eliminate
contaminating DNA, RNA was treated with DNase I (New
England Biolabs) for 30 min at 37uC and the DNase I heat
inactivated at 75uC for 10 min in the presence of 2 mM EDTA.
RNA concentrations were determined using a NanoDrop
spectrophotometer (ThermoScientific) and 300 ng/sample were
used to generate cDNA with Superscript III (Invitrogen) and
random hexamer primers (Fermentas). Levels of selected viral lytic












Primers were designed against the HSV-1 17syn
+ strain
reference sequence (GenBank NC_001806) using Primer 3 design
software [58]. Input RNA was normalized using 18S rRNA
primers (SA Biosciences) and the following equation: dCt
(threshold cycle)=Target gene Ct- 18s rRNA Ct. Real-time
qPCR analysis was performed using FastStart Universal SYBR
Green Master-ROX (Roche) and a MyiQ
TM single-color real-time
thermal cycler (BioRad). Relative changes in transcript levels were
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calculations were made using Prism 5.0 software (GraphPad).
Analysis of viral DNA replication
Neurons were washed in PBS, lysed with DNA extraction buffer
(150 mM NaCl, 10 mM Tris pH 8, 10 mM EDTA, 10% SDS)
and transferred to microcentrifuge tubes. Lysates were treated with
100 mg/ml Protease K overnight at 55uC, followed by two rounds
of phenol extraction, one round of chloroform extraction and
ethanol precipitation. DNA was re-suspended in water and
analyzed by qPCR using primers to HSV-1 UL30 and normalized
to cell number by amplification of rat RPL19 (RPL19 FW 59-
ATGTATCACAGCCTGTACCTG-39 and RPL19 RV 59-
TTCTTGGTCTCTTCCTCCTTG-39). To selectively inhibit
lytic DNA replication, 0.3 mg/ml phosphonoacetic acid (PAA,
Sigma) was added to the media 1 h before acute infection or with
LY294002 for reactivation.
Growth of HSV-1 stocks and titer determination
Viral stocks were amplified on Vero (GFP-Us11) or U2OS
(in1814, in1814R) cells. Semi-confluent monolayers were infected
at MOI=0.01 and maintained at 34uC for 2–3 days before
harvest by freeze-thaw lysis and sonication. Infectious titers were
determined by plaque assay using either Vero cells or rat embryo
fibroblasts. Uninfected cells were seeded at a density of 5610
5/
well in 6-well plates and incubated with lysate for 2 h at 37uC
before being overlaid with 0.5% agarose in MEM supplemented
with 1% calf serum. After incubation for 3 days at 37uC, cells were
fixed with 10% TCA for 15 min and stained with 1% crystal
violet.
Immunofluorescence microscopy
Neurons were seeded at density of 4–5610
4 onto coverslips
pre-coated with poly-D lysine, collagen and laminin and later
fixed using 4% paraformaldehyde/20% sucrose in PBS for
15 min, quenched with 100 mM ammonium chloride for 5 min
and permeabilized with 0.1% Triton X-100 in PBS. After
blocking in 1% BSA in PBS for 15 min, coverslips were
incubated with polyclonal antibodies against VP16 (a-VP16
pep153, diluted 1:1,000, a kind gift of Michael Gregory Peterson,
Tularik Inc.) for 2 h at room temperature or against HCF-1 (a-
rHCF H12 [59], diluted 1:1,000) and detected using Alexa555-
conjugated a-rabbit IgG antibody (diluted 1:1,000, 1 h at 37uC).
Nuclei were stained with 1 mg/ml 49, 6-diamidino-2-phenylindole
(DAPI) and the coverslips were mounted with DakoCytomation
fluorescent mounting medium (Dako Corp.). Samples were
visualized using a Zeiss LSM 510 META laser scanning confocal
microscope. Images were captured with the Zeiss AIM software
and exported into Adobe Photoshop 7.0 for cropping and minor
adjustments.
Protein extraction and immunoblotting
Cells were washed in PBS and then lysed in medium salt
extraction buffer (250 mM KCL, 20 mM Tris-HCl pH 7.9, 10%
glycerol, 0.25% NP40) on ice for 1 h. The supernatant was
collected after centrifugation for 10 min at 11,000 rpm at 4uC and
fractionated by 10% SDS-PAGE. Separated proteins were
transferred onto nitrocellulose membranes and blocked with 5%
milk in TBS-T (200 mM Tris, 1.4 M NaCl, 1% Tween) for
30 min at room temperature prior to incubation overnight at 4uC
with a-VP16 (diluted 1:1,000) or a-Rho-GDI (Santa Cruz, diluted
1:5,000), followed by HRP-conjugated a-rabbit IgG antibody
(Roche, diluted 1:2,500).
Lentiviral delivery of VP16 shRNA and human Oct-1
Depletion of HSV-encoded VP16 was achieved using shRNA
delivered into latently infected neurons by lentivirus (pLVTHM-
VP16shRNA). An oligonucleotide duplex 59-cgcgtccccGAGTG-
TAAATTCCTATCAATtcaagaGATTGATAGGAATTTACA-
CTCtttttggatccat-39 containing the hairpin sequence (upper case)
was inserted between the unique Mlu I and Cla I sites of a
pLVTHM derivative that has been modified to constitutively
express mCherry [14]. A human Oct-1 (GenBank NM_002697)
cDNA was expressed from lentiviral vector pEZ-Lv105 vector
(GeneCopoeia). Altered sense mutations (E30D/M33L) were
introduced by successive rounds of QuikChange II XL Site-
Directed Mutagenesis (Stratagene) and verified by DNA sequenc-
ing. Lentiviral stocks were generated by transfection of HEK
293LTV cells (Cell Biolabs) using calcium phosphate co-
precipitation to introduce a mixture of the lentiviral vector
plasmid and two packaging plasmids (pD8.9 and pMD2.G) in an
equal ratio. Precipitates were left on the cells overnight and then
washed. A control virus encoding GFP was prepared in the same
manner. Supernatants containing lentivirus were collected on days
3 and 4. To infect neuron cultures, 500 ml of lentiviral-containing
supernatant was added to each well, incubated overnight and
replaced with fresh media the following day. For latently infected
cultures, lentivirus was added 5 days after HSV-1 infection in the
presence of ACV and reactivation with LY294002 was performed
5 days after lentivirus infection.
Gel-shift analysis
Recombinant human Oct-1, VP16DC and HCF-1N380 were
synthesized by in vitro translation using the TNT quick-coupled
transcription/translation system (Promega) in the presence of
Easytag L-[
35S]-methionine (Perkin Elmer) as previously described
[60,61]. The E30D/M33L mutation was introduced into wild type
human Oct-1 by site-directed mutagenesis. A radiolabeled double-
stranded DNA probe was prepared by PCR amplification using
32P-labeled primers to amplify a subcloned ICP0 (OCTA+)-
TAATGARAT sequence [23]. Binding reactions containing
labeled probe, 1 mg poly-dI-dC, 10 mM Hepes pH 7.9, 75 mM
KCl, 1 mM EDTA, 10 mM DTT and up to 4 ml reticulocyte
lysate were incubated at room temperature for 20 min and loaded
on a 4% native polyacrylamide gel with 1x Tris-glycine-EDTA
buffer. Electrophoresis was carried out at room temperature and
run at a constant 170 V. Gels were fixed in methanol/acetic acid,
dried and the probe visualized by autoradiography using an X-ray
film to block the
35S signal.
Accession numbers
The Genbank (http://www.ncbi.nlm.nih.gov/Genbank/) ac-
cession number for the HSV-1 17syn
+ strain reference sequence is
NC_001806. Database accession numbers for proteins analyzed in
this study are: rat HCF-1 (NM_001139507.1); human Oct-1
(NP_002688); rat Oct-1 (NP_001094109), and VP16 (Swiss-Prot:
P04486.2).
Supporting Information
Figure S1 Acute replication of HSV-1 in primary rat
embryo fibroblasts (REFs). One day before infection, REFs
were seeded into 6-well plates at a density of 2.0610
5 cells/well.
The next day, HSV-1 GFP-Us11 was added at a multiplicity of 3
(MOI=3) and incubated at 4uC for 1.5 h to promote synchronous
infection. The temperature was then shifted to 37uC (time post
infection=0 h) and RNA and DNA samples were collected at
hourly intervals. (A) Quantitative reverse-transcription PCR to
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Because viral transcripts accumulated to very high levels (up to
10
6-fold increase), the fold change is plotted as a percentage of the
maximum value for each primer set over the 7 h period. Values
are the mean and standard error of the mean from two
independent infection experiments. (B) Quantitative PCR analysis
of viral genomic DNA using primers to the UL30 locus. Samples
were prepared from synchronous infection in presence or absence
of the viral DNA polymerase inhibitor PAA (300 mg/ml). Input
DNA was normalized using primers to the neuronal RPL19 gene.
(EPS)
Figure S2 VP16 contributes to viral gene expression
during Phase II. (A) Time course of viral mRNA accumulation
in SCG cultures latently infected with HSV-1 in1814 (MOI=1)
and induced to reactivate with 20 mM LY294002 in media lacking
ACV. (B) Quantitative PCR analysis of viral genomic DNA of
in1814 or in1814R at 0 or 72 hours in the presence or absence of
PAA. (C, D) Five days after infection with HSV-1 GFP-Us11 in
the presence of 100 mM acyclovir, SCG neurons were secondarily
infected with a lentivirus expressing an shRNA against VP16 (KD)
or control lentivirus (Con). After a further 5 days, the neurons were
treated with 20 mM LY294002 to induce reactivation. At various
times post treatment (15, 20, 48 or 72 h), total RNA was prepared
and assayed by RT-qPCR to determine relative amounts of VP16
transcript (C). As levels of VP16 mRNA increased with time, the
relative extent of knockdown also increased as shown here by
plotting the fold change between the control and VP16 shRNA
samples. (D) Viral mRNA accumulation over time course. Data is
derived from three independent experiments and values represent
the average and standard error of the mean.
(EPS)
Figure S3 Lytic proteins ICP0 and ICP27 are expressed
in Phase I and are localized to the nucleus. Week old SCG
neuronal cultures were infected with either in1814 (A) or HSV
GFP-Us11 (B) at MOI=1 in the presence of ACV. After one week
of establishing latency period, the cultures were induced with
media lacking ACV but containing 20 mM LY294002. Samples
were fixed either 25 hours (A) or 20 hours (B) after induction.
ICP0 was detected using a monoclonal antibody (Virusys, 1:100)
and ICP27 was detected with a polyclonal antibody (Abcam,
1:1000). Nuclei were stained with DAPI. Arrowheads indicate a
cluster of ICP0 speckles in the nucleus of two of the four neurons.
DIC, differential interference contrast microscopy.
(TIF)
Figure S4 Nuclear localization of the HCF-1 associated
factors Ash2L and LSD1 in HeLa cells and unstimulated
SCG neurons. SCG-derived neurons were seeded onto glass
coverslips and cultured for 7 days under conditions that support
the establishment of HSV-1 latency before being fixed with 4%
PFA. After quenching with 100 mM ammonium chloride, the
samples were permeabilized with 0.1% Triton-X 100 and blocked
using 1% BSA. Coverslips were incubated with either a-Ash2L
(diluted 1:1000) or a-LSD1 (diluted 1:400) antibodies for 2 h
followed by a fluorescent secondary antibody. HeLa cells served as
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